GRAPE KING   Report issue

For profit
Founded: Taoyuan Taiwan (1969)
Status: No NME R&D (1969)

Organization Overview

First Clinical Trial
2012
NCT01598064
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Grape King Bio Ltd.

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 5
  • # of Trial APIs: 4